Newest studies

Psychometric properties of International HIV Dementia Scale as screening tool for neurocognitive disorder among people living with HIV/AIDS

42/100 ✓ Peer-reviewed Cognitive tests and assessment Scientific Reports

Key finding: Multivariable linear regression analysis indicated that being married (β = 0.6, p-value = 0.02) and being a young adult (β = 0.52, p-value = 0.04) were significantly associated with better neurocognitive performance.

• Diagnosis

Full summary, score breakdown and related studies → Original source

Revealing the nervous system requirements of Alzheimer disease risk genes in Drosophila

34/100 ✓ Peer-reviewed Risk genes beyond APOE The American Journal of Human Genetics

Key finding: Overall, we identify 50 candidate AD risk gene homologs with requirements for CNS structure or function, including 18 whose loss of function causes neurodegeneration (e.g., Snx6/SNX32 and ClC-a/CLCN1), 35 required for neurophysiology (e.g., Arr1/ARRB2 and stai/STMN4), and eight with diminished CNS resilience following a thermal or mechanical stress (e.g., cindr/CD2AP and Amph/BIN1). +3 more findings

• Genetics

Full summary, score breakdown and related studies → Original source

Atrophy patterns of deep gray matter nuclei in Alzheimer's disease and frontotemporal dementia

55/100 ✓ Peer-reviewed Lewy body dementia Journal of Alzheimer s Disease

Key finding: A hierarchical Random Forest model was trained to classify diagnostic groups. +2 more findings

• Other Dementias

Full summary, score breakdown and related studies → Original source

Enhancing dementia risk prediction with heart rate and machine learning in the Canadian Longitudinal Study on Aging

59/100 ✓ Peer-reviewed Digital health tools Journal of Alzheimer s Disease

Key finding: Incorporating RHR into the CAIDE model led to a significant improvement in predictive accuracy. +2 more findings

• Risk Factors
• Digital Tools

Full summary, score breakdown and related studies → Original source

Interplay between astrocyte reactivity and APOE ε4 status is associated with accelerated pTau-related tau pathology in Alzheimer's disease

59/100 ✓ Peer-reviewed Laboratory science Molecular Neurodegeneration

Key finding: Plasma GFAP and pTau biomarkers (pTau181, pTau231, pTau217) are significantly elevated in Aβ-positive individuals, with stronger Aβ–pTau associations observed in APOE ε4 carriers (CPAS: β = 0.26, p = 0.003 for pTau231; ADNI: β = 0.45, p < 0.001 for pTau181). +4 more findings

• Brain Biology
• Genetics
• Biomarkers

Full summary, score breakdown and related studies → Original source

TDP-43-proteinopathy at the crossroads of tauopathy: on copathology and current and prospective biomarkers

43/100 ✓ Peer-reviewed Brain tissue and pathology Frontiers in cellular neuroscience

Key finding: Though usually described as isolated models, neurodegenerative diseases exist in a significant proportion of cases as mixed pathologies, particularly in older adults.

• Brain Biology
• Biomarkers

Full summary, score breakdown and related studies → Original source

Whole-genome Sequence Analysis Revealed Novel Subjective Cognitive Decline-associated Genes in 10,763 Chinese

57/100 ✓ Peer-reviewed Genetics Genomics, proteomics & bioinformatics

Key finding: To address this gap, we investigated genetic biomarkers associated with SCD using whole-genome sequencing (WGS) in 10,763 Chinese participants from the Healthy Zhejiang One Million People Cohort (HOPE Cohort). +4 more findings

• Genetics
• Early Stage

Full summary, score breakdown and related studies → Original source

Expanding Prior Authorization in Traditional Medicare—The WISeR Model

44/100 ✓ Peer-reviewed Health systems and care delivery JAMA

Key finding: This Viewpoint discusses the Wasteful and Inappropriate Service Reduction (WISeR) model, a new payment model announced by the Centers for Medicare &amp;amp;amp; Medicaid Services Innovation Center to broaden prior authorization in traditional Medicare.

• Policy

Full summary, score breakdown and related studies → Original source

Psychotropic medications versus non-pharmacologic approaches for managing behavioural and psychological symptoms in Australian aged care residents with dementia: general practitioners’ and physicians’ perspectives

36/100 ✓ Peer-reviewed Clinical safety Therapeutic Advances in Psychopharmacology

Key finding: Four GPs and eleven physicians were interviewed, and four major themes emerged: (1) knowledge of best practices of BPSD management, (2) awareness of current challenges in BPSD management, (3) non-involvement, blame shifting and rationalisation: perceived reasons for the current challenges and (4) suggested solutions. +4 more findings

• Treatments

Full summary, score breakdown and related studies → Original source

Financial strain and depressive symptoms among parent‐child dyads coping with dementia, depression, or delirium

39/100 ✓ Peer-reviewed Clinical safety Alzheimer s & Dementia Behavior & Socioeconomics of Aging

Key finding: Study 1 showed that each person's financial strain was associated with their own greater depressive symptoms. +1 more finding

Full summary, score breakdown and related studies → Original source

Assessing Cognitive Decline and Dementia Risk in Black and White Older Adults With Blood Biomarkers pTau217, GFAP, NfL, and Aβ Ratio

66/100 ✓ Peer-reviewed Biomarkers Neurology

Key finding: Biomarkers were measured in 431 Black and 583 White participants (mean age of 77 and 80 years and 17% and 21% of men, respectively), generating a balanced sample of 366:366. +2 more findings

• Biomarkers
• Risk Factors
• Diagnosis

Full summary, score breakdown and related studies → Original source

Adoption of Telemedicine for Dementia Care in Nigeria: Scoping Review

82/100 ✓ Peer-reviewed Caregiving Interactive journal of medical research

Key finding: Among the 23 studies, 10 (43.5%) focused on mobile health apps, 8 (34.8%) on video consultations, and 5 (21.7%) on remote monitoring tools. +4 more findings

• Digital Tools

Full summary, score breakdown and related studies → Original source

Risk reduction and precision prevention across the Alzheimer's disease continuum: a systematic review of clinical trials combining multidomain lifestyle interventions and pharmacological or nutraceutical approaches

71/100 ✓ Peer-reviewed Prevention trials The journal of prevention of Alzheimer's disease

Key finding: To effectively combat dementia onset and progression, lifestyle-based interventions targeting multiple risk factors and disease mechanisms through a multidomain approach - tailored and implemented early in the disease process - have emerged as promising.

• Prevention
• Lifestyle
• Clinical Trials

Full summary, score breakdown and related studies → Original source

Combining a computerized cognitive test with serum biomarkers improves detection of early-onset neurodegenerative disorders

55/100 ✓ Peer-reviewed Cognitive tests and assessment Journal of Alzheimer's disease : JAD

Key finding: FAT was compared to traditional neuropsychological tests.

• Diagnosis
• Biomarkers
• Early Stage

Full summary, score breakdown and related studies → Original source

Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies

56/100 ✓ Peer-reviewed Inflammation and the immune system Molecular neurodegeneration

Key finding: Overall, antidiabetic medications represent a promising therapeutic strategy to tackle neurodegeneration and cognitive decline in AD preclinical models.

• Treatments
• Brain Biology
• Early Stage

Full summary, score breakdown and related studies → Original source

Lecanemab Therapy Use Patterns for Alzheimer's Disease Among Early Initiators in a Large National Health Plan

44/100 ✓ Peer-reviewed Health systems and care delivery Journal of the American Geriatrics Society

Key finding: The increase in new initiators was modest over 2024, with only 43 more initiators during the final (n = 137) versus the first quarter (n = 94) of 2024. +1 more finding

• Treatments

Full summary, score breakdown and related studies → Original source

White Matter Hyperintensities Moderate the Association Between Diabetes and Non-AD Brain Atrophy

52/100 ✓ Peer-reviewed Vascular contributions Diabetes Care

Key finding: Diabetes was not associated with brain atrophy cross-sectionally or longitudinally. +4 more findings

• Brain Scans
• Risk Factors

Full summary, score breakdown and related studies → Original source

Characterization of endothelin-converting enzyme 1 as a key enzyme in the multienzyme Aβ degradation pathway

36/100 ✓ Peer-reviewed Risk genes beyond APOE Proceedings of the National Academy of Sciences

Key finding: Notably, we found that ECE1 cleaves Aβ34, an indicator of amyloid clearance, to a unique and unusually stable Aβ20-34 fragment that has the potential to serve as a measurable biomarker. +1 more finding

• Brain Biology

Full summary, score breakdown and related studies → Original source

The role for artificial intelligence in identifying combination therapies for Alzheimer’s disease

39/100 ✓ Peer-reviewed Digital health tools The Journal of Prevention of Alzheimer s Disease

Key finding: This underscores the significant unmet need for identifying effective disease-modifying therapies.

• Digital Tools
• Treatments

Full summary, score breakdown and related studies → Original source

An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program

64/100 ✓ Peer-reviewed Prevention and risk JAMA

Key finding: A total of 368 participants were included (median [IQR] age, 58 [50-65] years; 71% were female, 27% were Black, 6% were Hispanic, and 61% were White; median [IQR] BMI, 32.3 [28.5-37.1]). +4 more findings

• Clinical Trials
• Prevention
• Risk Factors

Full summary, score breakdown and related studies → Original source

Diet, Exercise, and Lifestyle in Glaucoma: Current Evidence and Future Perspectives

51/100 ✓ Peer-reviewed Prevention and risk Nutrients

Key finding: Emerging evidence suggests that modifiable lifestyle factors may influence these pathogenic pathways. +2 more findings

• Lifestyle
• Prevention
• Brain Biology

Full summary, score breakdown and related studies → Original source

Alzheimer Combination Therapies: Overview and Scenarios

41/100 ✓ Peer-reviewed Treatments The Journal of Prevention of Alzheimer s Disease

Key finding: Phase 2 trials may use a 2-by-2 factorial design comparing each drug to placebo and the drug combination. +4 more findings

• Treatments
• Clinical Trials
• Brain Biology

Full summary, score breakdown and related studies → Original source

Common pathogenic mechanisms in the hippocampus across neurodegenerative dementias: Alzheimer's disease, Down syndrome, and Parkinson's disease

41/100 ✓ Peer-reviewed Down syndrome and Alzheimer's NPJ dementia

Key finding: For these neurodegenerative dementias, we observed that the chronological age did not align with their biological age, which was determined based on hippocampal transcript levels (i.e., transcriptional age). +3 more findings

• Down Syndrome
• Other Dementias

Full summary, score breakdown and related studies → Original source

Protein misfolding and its dual role in neurodegeneration and cancer progression

43/100 ✓ Peer-reviewed Disease mechanisms Advances in protein chemistry and structural biology

Key finding: In neurodegenerative diseases such as Huntington's disease (HD), Parkinson's disease (PD), Alzheimer's disease (AD), Amyotrophic lateral Sclerosis (ALS), chronic misfolding results in toxic protein aggregates like amyloid-β, tau, and α-synuclein.

• Brain Biology
• Other Dementias

Full summary, score breakdown and related studies → Original source

Identification of Hasegawa Dementia Scale‐Revised Cutoff Scores Associated With Mini‐Mental State Examination Thresholds for Anti‐Amyloid β Therapies in Patients With Amnesia

42/100 ✓ Peer-reviewed Cognitive tests and assessment Psychogeriatrics

Key finding: Of 234 patients, 143 (61.1%) were Aβ-positive. +4 more findings

• Treatments

Full summary, score breakdown and related studies → Original source